Insider Trading January 28, 2026

Intuitive Surgical Director Sells $14.48M in Stock as Company Posts Strong Q4 Results

Director Gary S. Guthart executed share sales and option exercises under a 10b5-1 plan as analysts respond to better-than-expected quarterly performance

By Jordan Park ISRG
Intuitive Surgical Director Sells $14.48M in Stock as Company Posts Strong Q4 Results
ISRG

Intuitive Surgical director Gary S. Guthart sold 27,300 shares on January 27, 2026, receiving $14,475,672, and on the same day exercised options to acquire 25,500 shares at $174.2567 per share. The trades were carried out under a pre-set SEC Rule 10b5-1 plan that expires April 28, 2026. The company reported robust fourth-quarter 2025 results with $2.87 billion in revenue, exceeding several analyst forecasts and prompting multiple firm upgrades and reiterated Buy ratings.

Key Points

  • Director Gary S. Guthart sold 27,300 shares on January 27, 2026, for $14,475,672 in multiple transactions priced between $530.0981 and $531.5285.
  • Guthart also exercised options to acquire 25,500 shares at $174.2567 on the same day, representing $4,443,545 in value; both actions were executed under a 10b5-1 plan expiring April 28, 2026.
  • Intuitive Surgical reported Q4 2025 revenue of $2.87 billion, a 19% increase year-over-year, beating Stifel and consensus estimates and prompting several analyst upgrades and reiterated Buy ratings.

Transaction details

Gary S. Guthart, who serves on the board of Intuitive Surgical Inc (NASDAQ:ISRG), disposed of 27,300 shares of the company's common stock on January 27, 2026. The sales were completed in multiple tranches at prices spanning from $530.0981 to $531.5285, resulting in aggregate proceeds of $14,475,672.

Concurrent option exercise

On the same date, Guthart exercised stock options to obtain 25,500 shares of Intuitive Surgical common stock at an exercise price of $174.2567 per share, representing a total notional value of $4,443,545. Both the sales and the option exercise were implemented through a pre-arranged trading program compliant with SEC Rule 10b5-1. That plan is scheduled to lapse on April 28, 2026.

Quarterly performance and guidance highlights

Intuitive Surgical posted fourth-quarter 2025 revenue of $2.87 billion, a year-over-year increase of 19%, a result that topped Stifel and consensus estimates of $2.72 billion. According to commentary within analyst notes, the company beat expectations on earnings per share and revenue by roughly 11% and 4%, respectively, as observed by RBC Capital. Guidance for gross margins in 2026 was noted by Truist Securities to reflect a 90 basis point improvement compared with the prior year.

Analyst reactions

Market analysts responded to the quarterly results and company commentary with a string of positive ratings and target revisions. TD Cowen initiated coverage with a Buy rating and a $660.00 price target, identifying Intuitive Surgical as a core holding in MedTech. Freedom Capital Markets upgraded its view from Hold to Buy and set a $610.00 target, attributing its move in part to expectations tied to the da Vinci 5 surgical system rollout. Stifel and Truist Securities both maintained Buy ratings with respective price targets of $670.00 and $650.00. RBC Capital kept an Outperform rating with a $650.00 target following the quarter it described as robust.

Context and close

The insider sales and option exercise occurred alongside a quarterly report that outperformed several street estimates and prompted positive analyst activity. The trades took place under an established 10b5-1 plan, with the plan set to expire in late April 2026.

Risks

  • Insider sales occurred despite strong quarterly results, which may introduce short-term market uncertainty for the MedTech and healthcare equipment sectors.
  • The 10b5-1 plan governing the director's trades is set to expire on April 28, 2026, leaving future insider activity uncertain for the near term.
  • Analyst optimism and upgraded price targets depend on execution of product rollouts and margin improvement guidance; failure to meet those expectations could affect MedTech valuations and investor sentiment.

More from Insider Trading

Clean Harbors Director Executes $204,802 Sale as Company Reports Strong Q4 and Pushes M&A Agenda Feb 21, 2026 Clean Harbors Executive Disposes Nearly $1.0M in Stock as Company Posts Strong Q4 Feb 21, 2026 Clean Harbors CFO Disposes $784K in Shares as Company Reports Strong Quarter and Pursues Acquisition Feb 21, 2026 Travelers Executive Vice President Records $1.74 Million Share Sale as Company Posts Strong Quarter Feb 21, 2026 Genasys Director Buys $50,404 of Stock; Company Reports Mixed Q1 Results Feb 21, 2026